

UNITED STATES SECURITIES AND  
EXCHANGE COMMISSION  
Washington, D.C. 20549

Schedule 13G  
(RULE 13d-102)

Under the Securities Exchange Act of 1934  
(Amendment No. )\*

Information to be included in statements filed  
pursuant to Rule 13d-1 (b) (c) and (d) and Amendments thereto  
filed pursuant to Rule 13d-2 (b).

Titan Pharmaceuticals, Inc.  
(Name of Issuer)

Common Stock  
(Title of Class of Securities)

888314101  
(CUSIP Number)

January 31, 2010  
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant  
to which this Schedule is filed:

- Rule 13d-1 (b)  
 Rule 13d-1 (c)  
 Rule 13d-1 (d)

\*The remainder of this cover page shall be filled out for a  
reporting person's initial filing on this form with respect to the  
subject class of securities, and for any subsequent amendment  
containing information which would alter the disclosures provided  
in a prior cover page.

The information required in the remainder of this cover page shall  
not be deemed to be "filed" for the purpose of Section 18 of the Securities  
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of  
that section of the Act but shall be subject to all other provisions of  
the Act (however, see the Notes).

SCHEDULE 13G

Issuer: Titan Pharmaceuticals, Inc. CUSIP No.: 888314101

1 NAMES OF REPORTING PERSONS I.R.S.  
IDENTIFICATION NOS. OF ABOVE PERSONS

First Eagle Investment Management, LLC  
Tax ID # 57-1156902

2 CHECK THE APPROPRIATE BOX IF A MEMBER  
OF A GROUP

- (a)  
(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION  
State of Delaware

NUMBER OF SHARES	5	SOLE VOTING POWER - 7,986,744
BENEFICIALLY	6	SHARED VOTING POWER - 0
OWNED BY EACH	7	SOLE DISPOSITIVE POWER - 7,986,744
REPORTING PERSON	8	SHARED DISPOSITIVE POWER - 0

WITH:

9 AGGREGATE AMOUNT BENEFICIALLY OWNED  
BY EACH REPORTING PERSON

7,986,744

10 CHECK IF THE AGGREGATE AMOUNT IN  
ROW (11) EXCLUDES CERTAIN SHARES

N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT  
IN ROW 9:

13.13%

12 TYPE OF REPORTING PERSON

IA

SCHEDULE 13G

Issuer: Titan Pharmaceuticals, Inc. CUSIP No.: 888314101

ITEM 1

(a) Name of Issuer:

Titan Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

400 Oyster Point Blvd., Suite 505  
South San Francisco, CA 94080

ITEM 2

(a) Name of Person Filing: First Eagle Investment Management, LLC

(b) Address of Principal Business Office:

1345 Avenue of the Americas  
New York, NY 10105

(c) Citizenship: Delaware, USA (Place of Incorporation)

(d) Title of Class of Securities: Common Stock

(e) CUSIP Number: 888314101

SCHEDULE 13G

Issuer: Titan Pharmaceuticals, Inc. CUSIP No.: 888314101

ITEM 3

If this statement is filed pursuant to Sections 240.

13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

- (a)  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
- (b)  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c)  Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78C);
- (d)  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e)  An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
- (h)  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i)  A church plan that is excluded from the definition of an insurance company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

SCHEDULE 13G

Issuer: Titan Pharmaceuticals, Inc. CUSIP No.: 888314101

ITEM 4. Ownership.

(a) Amount beneficially owned: 7,986,744

(b) Percent of class: 13.13%

(c) Number of shares as to which the person has:

- (i) Sole power to vote or to direct the vote 7,986,744
- (ii) Shared power to vote or to direct the vote 0
- (iii) Sole power to dispose or to direct the disposition of 7,986,744
- (iv) Shared power to dispose or to direct the disposition of 0

ITEM 5. Ownership of Five Percent or Less of a Class.

N/A

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

First Eagle Investment Management, LLC (FEIM), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, may be deemed currently to be the beneficial owner of 7,986,744 common shares (assuming exercise of warrants to acquire 1,562,500 shares of the Issuer's common stock), or 13.13% of the Issuer's common stock currently

outstanding (assuming exercise of the 1,562,500 warrants noted above), as a result of acting as investment adviser to various clients. This filing is being made as a result of the effectiveness of the issuer filing a registration statement registering the common shares under Section 12 of the Exchange Act. Clients of FEIM have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON.

N/A

ITEM 8. Identification and Classification of Members of the Group.

N/A

ITEM 9. Notice of Dissolution of Group

N/A  
SCHEDULE 13G

Issuer: Titan Pharmaceuticals, Inc. CUSIP No.: 888314101

ITEM 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose of effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 5, 2010

Signature: /s/ Mark Goldstein

Name/Title: Mark Goldstein, Senior Vice President

</PAGE>